Ibrexafungerp

CHEMBL4297513 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
730.0 g/mol
LogP
5.8
Phase
4

This first-in-class glucan synthase inhibitor treats vulvovaginal candidiasis with oral activity against azole-resistant Candida strains.

Berat Molekul

730,0000 g/mol

LogP

5,80

TPSA

125,00 Ų

Lipinski RO5

Gagal

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(C)[C@@H](C)[C@@]1(C)CC[C@]2(C)[C@H]3CC[C@@H]4[C@@]5(COC[C@@]4(C)[C@@H](OC[C@](C)(N)C(C)(C)C)[C@H](n4ncnc4-c4ccncc4)C5)C3=CC[C@@]2(C)[C@@H]1C(=O)O

InChI

InChI=1S/C44H67N5O4/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+/m1/s1

Molecular Formula

C44H67N5O4

HBD / HBA

2 / 8

Ikatan yang Dapat Dirotasi

9

Atom Berat

53

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This first-in-class glucan synthase inhibitor treats vulvovaginal candidiasis with oral activity against azole-resistant Candida strains.

Yes, Ibrexafungerp is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297513. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 46871657. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.